Comparative virology and pathology of Monkeypox virus in Syrian hamsters, C57BL/6, and BALB/c mice: A framework for preclinical model selection

Abstract

Monkeypox virus (MPXV), a zoonotic orthopoxvirus, has emerged as a major public health concern following its global spread in 2022. Robust small animal models are urgently needed to investigate MPXV pathogenesis and evaluate medical countermeasures. Here, we systematically compared MPXV infection in Syrian hamsters, C57BL/6 mice, and BALB/c mice following intraperitoneal inoculation. Syrian hamsters displayed the highest susceptibility, with systemic viral dissemination peaking at 2 days post-infection (dpi) and clearance by 12 dpi. Viral burdens were particularly elevated in the spleen and kidneys, correlating with severe histopathological changes. In contrast, C57BL/6 and BALB/c mice exhibited more restricted viral replication, with the kidneys, liver, and spleen serving as major target organs. Across all models, no cutaneous lesions were observed, underscoring the influence of infection route on disease phenotype. Comparative analysis revealed species-specific tissue tropism and clearance kinetics, confirming the Syrian hamster as a permissive model for systemic MPXV disease, while C57BL/6 and BALB/c mice offer complementary value for mechanistic immunology studies. These findings establish a framework for rational selection of small animal models to study MPXV pathogenesis and to evaluate antiviral and vaccine strategies.

Keywords

Monkeypox virus / rodent models / viral pathogenesis / viral replication kinetics / viral tissue tropism

References

[1] McCollum AM, Damon IK. Human monkeypox. Clin Infect Dis. 2014; 58(2): 260-267.

[2] Wawina-Bokalanga T, Merritt S, Kinganda-Lusamaki E, et al. Epidemiology and phylogenomic characterisation of two distinct mpox outbreaks in Kinshasa, DR Congo, involving a new subclade Ia lineage: a retrospective, observational study. Lancet. 2025; 406(10498): 63-75.

[3] Nishiyama T, Miura F, Jeong YD, et al. Modeling lesion transition dynamics to clinically characterize patients with clade I mpox in The Democratic Republic of the Congo. Sci Transl Med. 2025; 17(805):eads4773.

[4] Mitjà O, Ogoina D, Titanji BK, et al. Monkeypox. Lancet. 2023; 401(10370): 60-74.

[5] Isidro J, Borges V, Pinto M, et al. Phylogenomic characterization and signs of microevolution in the 2022 multi-country outbreak of monkeypox virus. Nat Med. 2022; 28(8): 1569-1572.

[6] Thornhill JP, Barkati S, Walmsley S, et al. Monkeypox virus infection in humans across 16 countries - April-June 2022. N Engl J Med. 2022; 387(8): 679-691.

[7] Beer EM, Rao VB. A systematic review of the epidemiology of human monkeypox outbreaks and implications for outbreak strategy. PLoS Negl Trop Dis. 2019; 13(10):e0007791.

[8] Vaughan A, Aarons E, Astbury J, et al. Human-to-human transmission of Monkeypox virus, United Kingdom, October 2018. Emerg Infect Dis. 2020; 26(4): 782-785.

[9] Moss B. Understanding the biology of monkeypox virus to prevent future outbreaks. Nat Microbiol. 2024; 9(6): 1408-1416.

[10] Huang Y, Mu L, Wang W. Monkeypox: epidemiology, pathogenesis, treatment and prevention. Signal Transduct Target Ther. 2022; 7(1): 373.

[11] Likos AM, Sammons SA, Olson VA, et al. A tale of two clades: monkeypox viruses. J Gen Virol. 2005; 86(Pt 10): 2661-2672.

[12] Chen N, Li G, Liszewski MK, et al. Virulence differences between monkeypox virus isolates from West Africa and The Congo basin. Virology. 2005; 340(1): 46-63.

[13] Patel A, Bilinska J, Tam JCH, et al. Clinical features and novel presentations of human monkeypox in a central London centre during the 2022 outbreak: descriptive case series. BMJ. 2022; 378:e072410.

[14] Adler H, Gould S, Hine P, et al. Clinical features and management of human monkeypox: a retrospective observational study in the UK. Lancet Infect Dis. 2022; 22(8): 1153-1162.

[15] Philpott D, Hughes CM, Alroy KA, et al. Epidemiologic and clinical characteristics of Monkeypox cases - United States, may 17-July 22, 2022. MMWR Morb Mortal Wkly Rep. 2022; 71(32): 1018-1022.

[16] Earl PL, Americo JL, Wyatt LS, et al. Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature. 2004; 428(6979): 182-185.

[17] Li Q, Chen Y, Zhang W, et al. Mpox virus clade IIb infected Cynomolgus macaques via mimic natural infection routes closely resembled human mpox infection. Emerg Microbes Infect. 2024; 13(1):2332669.

[18] Zuiani A, Dulberger CL, De Silva NS, et al. A multivalent mRNA monkeypox virus vaccine (BNT166) protects mice and macaques from orthopoxvirus disease. Cell. 2024; 187(6): 1363-1373.e12.

[19] Guarner J, Johnson BJ, Paddock CD, et al. Monkeypox transmission and pathogenesis in prairie dogs. Emerg Infect Dis. 2004; 10(3): 426-431.

[20] Schultz DA, Sagartz JE, Huso DL, Buller RM. Experimental infection of an African dormouse (Graphiurus kelleni) with monkeypox virus. Virology. 2009; 383(1): 86-92.

[21] Falendysz EA, Lopera JG, Doty JB, et al. Characterization of Monkeypox virus infection in African rope squirrels (Funisciurus sp.). PLoS Negl Trop Dis. 2017; 11(8):e0005809.

[22] Tesh RB, Watts DM, Sbrana E, Siirin M, Popov VL, Xiao SY. Experimental infection of ground squirrels (Spermophilus tridecemlineatus) with monkeypox virus. Emerg Infect Dis. 2004; 10(9): 1563-1567.

[23] Wei X, Yang H, Wu J, et al. Immune imprinting blunts omicron pathogenicity fluctuations and highlights the essential role of cellular immunity in SARS-CoV-2 infection. Cell Rep. 2025; 44(6):115784.

[24] Ruedas-Torres I, Findlay-Wilson S, Kennedy E, Dowall S, Salguero FJ. Pathology and host-pathogen interactions in a golden Syrian hamster model of Nipah virus infection. Front Vet Sci. 2025; 12:1518358.

[25] Scharton D, Van Wettere AJ, Bailey KW, et al. Rift Valley fever virus infection in golden Syrian hamsters. PLoS One. 2015; 10(1):e0116722.

[26] Iwatsuki-Horimoto K, Nakajima N, Ichiko Y, et al. Syrian hamster as an animal model for the study of human influenza virus infection. J Virol. 2018; 92(4):e01693-17.

[27] Baoying H, Hua Z, Jingdong S, et al. Isolation and characterization of Monkeypox virus from the first case of Monkeypox — Chongqing municipality, China, 2022. China CDC Wkly. 2022; 4(46): 1019-1024.

[28] Ogoina D, Iroezindu M, James HI, et al. Clinical course and outcome of human Monkeypox in Nigeria. Clin Infect Dis. 2020; 71(8): e210-e214.

[29] Yinka-Ogunleye A, Aruna O, Dalhat M, et al. Outbreak of human monkeypox in Nigeria in 2017-18: a clinical and epidemiological report. Lancet Infect Dis. 2019; 19(8): 872-879.

[30] Hutson CL, Damon IK. Monkeypox virus infections in small animal models for evaluation of anti-poxvirus agents. Viruses. 2010; 2(12): 2763-2776.

[31] Miao J, Chard LS, Wang Z, Wang Y. Syrian hamster as an animal model for the study on infectious diseases. Front Immunol. 2019; 10:2329.

[32] Stabenow J, Buller RM, Schriewer J, West C, Sagartz JE, Parker S. A mouse model of lethal infection for evaluating prophylactics and therapeutics against Monkeypox virus. J Virol. 2010; 84(8): 3909-3920.

[33] Americo JL, Moss B, Earl PL. Identification of wild-derived inbred mouse strains highly susceptible to monkeypox virus infection for use as small animal models. J Virol. 2010; 84(16): 8172-8180.

[34] Saha P, Xiao X, Li Y, et al. Distinct iron homeostasis in C57BL/6 and Balb/c mouse strains. Physiol Rep. 2020; 8(9):e14441.

[35] Schulte S, Sukhova GK, Libby P. Genetically programmed biases in Th1 and Th2 immune responses modulate atherogenesis. Am J Pathol. 2008; 172(6): 1500-1508.

[36] Bleul T, Zhuang X, Hildebrand A, et al. Different innate immune responses in BALB/c and C57BL/6 strains following corneal transplantation. J Innate Immun. 2021; 13(1): 49-59.

[37] Reynolds MG, Damon IK. Outbreaks of human monkeypox after cessation of smallpox vaccination. Trends Microbiol. 2012; 20(2): 80-87.

RIGHTS & PERMISSIONS

2026 The Author(s). Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.